According to the Appendix, SOLSTICE met its primary endpoint, demonstrating clinically meaningful HbA1c reductions over 26 weeks in adults with type 2 diabetes. In obesity and overweight, the Phase IIb VISTA trial (NCT06579092) assessed multiple oral doses of elecoglipron versus placebo, using coprimary endpoints of percentage change in body weight and the proportion of participants achieving at least 5% weight loss at 26 weeks
We reserve the right to refuse or cancel any order for any reason, including product availability, pricing errors, or suspected fraud
1) that contained all expected components were vitrified and imaged by single-particle cryo-EM on a 300 kV Titan Krios, with (oxyntomodulin) or without (exendin-4) a Volta Phase Plate (VPP)
Transdermal Preferred We prioritize transdermal estradiol delivery for its superior safety profile regarding clotting and cardiovascular risk
If you do not like the taste of any of the meals in your first order, we will refund or swap them for you
For a more detailed description and lab analysis, please see the sections below